

# TrippBio Announces Initiation of the Phase 2 Study to Evaluate PanCytoVir™ in Patients with Mild-to-Moderate COVID-19

*First patient screened in study to define the antiviral effect of PanCytoVir™ in patients with mild-to-moderate COVID-19*

JACKSONVILLE, FL, UNITED STATES, July 19, 2022 /EINPresswire.com/ --

TrippBio, Inc. (TrippBio), a clinical development-stage biopharmaceutical company developing antiviral treatments announces that the first patient was screened in the Phase 2, dose-range finding study with PanCytoVir™ in patients with mild-to-


moderate COVID-19 ([NCT05442983](#)). The study will enroll up to 75 non-hospitalized patients with symptomatic, mild-to-moderate COVID-19 infection. Patients will be randomly assigned to one of three treatment groups: 500 mg twice daily, 1000 mg twice daily, or matching-placebo twice daily and treated for 5 days. Topline results from this study are expected in 3Q22.

“

We are pleased to announce the start of our clinical program for PanCytoVir™ in COVID-19. This study will allow us to identify a safe and effective dose that we can use in our registrational studies.”

*Dr. David E. Martin*

David E. Martin, PharmD, and CEO of TrippBio, Inc., stated, “We are pleased to announce the start of our clinical development program for PanCytoVir™ in COVID-19. While the peak of the pandemic has hopefully passed, we must remain vigilant and continue to develop antiviral therapies that are not only clinically effective but are also cost-effective as COVID-19 evolves into an endemic disease that we will have to manage for years to come. This study will allow us to identify a safe and effective dose that we can use in our registrational studies.”



PanCytoVir™

PanCytoVir™ (formerly known as TD-213) is a repurposed pharmaceutical approved by the FDA

for the treatment of the hyperuricemia associated with gout and can be used as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin for prolonging drug plasma levels. PanCytoVir™ is a favorable antiviral drug candidate as it is commercially available and has high plasma concentrations with a benign clinical safety profile. It has demonstrated potent activity against SARS-CoV-2 [1] influenza [2], and RSV [3] in vitro and in animal models of infection. PanCytoVir™ analogs are compounds with improved solubility characteristics and the potential for new formulation development.

#### About TrippBio, Inc.

TrippBio, Inc. is a Jacksonville, Florida-based, clinical development-stage biopharmaceutical company dedicated to commercializing new applications of therapeutics to fight infectious diseases with an emphasis on viral diseases with current efforts focused on the identification of drugs to combat infections such as the SARS-CoV-2 virus that causes COVID-19. TrippBio is founded on the scientific research of Ralph Tripp, Ph.D., Georgia Research Alliance Chair and Professor at the University of Georgia. The University of Georgia Research Foundation is a major shareholder of TrippBio, Inc.

1. Murray J, Hogan RJ, Martin DE, et al. Probenecid potently inhibits SARS-CoV-2 replication in vivo and in vitro. Scientific Reports 2021;11;18085 (<https://doi.org/10.1038/s41598-021-97658-w>).
2. Berwitasari O, Yan X, Johnson S et al. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza virus strategy. Antimicrob Agents Chemother 57(1), 475-483 (2013).
3. Murray J, Bergeron H, Shepard J, et al. Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication. Viruses 2022, 14, 912.

David Martin

TrippBio, Inc.

davidmartin@trippbio.com

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/580963116>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.

# TrippBio and University of Georgia Research Foundation Expand Licensing Agreement for PanCytoVir™ and Analogs

*The revised agreement broadens TrippBio's pipeline with new chemical entities that show promise as broadly active anti-viral treatments*

JACKSONVILLE, FL, USA, July 26, 2022 /[EINPresswire.com](https://www.einpresswire.com/)/ -- TrippBio, Inc. (TrippBio), a clinical development-stage biopharmaceutical company developing antiviral treatments and the University of Georgia Research Foundation (UGARF), today announced that they have signed an amendment to their 21 May 2020 License Agreement expanding cooperation to include additional new chemical entities that have shown promise as broadly active antiviral compounds. Multiple new compounds based on PanCytoVir™ chemistry have been prepared and will be investigated in upcoming preclinical studies. Recent data suggests that PanCytoVir™ and possibly its analogs may be safe and effective therapeutics for other important viral infections including measles, mumps, Dengue, and Zika viruses.

David E. Martin, PharmD, and CEO of TrippBio, Inc., stated, "We are pleased to extend and expand a very successful collaboration between TrippBio, Inc and Dr. Ralph Tripp of the University of Georgia. This expanded Licensing Agreement will allow us to aggressively pursue these additional indications and importantly will give us new composition of matter protection for these new indications. We look forward to sharing more on our pipeline expansion in the very near future."

**This expanded Agreement will allow us to aggressively pursue additional indications and importantly will give us new composition of matter protection for these new indications. "**

— Dr. David E. Martin

## PanCytoVir™

PanCytoVir™ (formerly known as TD-213) is a repurposed pharmaceutical approved by the FDA for the treatment of the hyperuricemia associated with gout and can be used as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin for prolonging drug plasma levels. PanCytoVir™ is a favorable antiviral drug candidate as it is commercially available and has high plasma concentrations with a benign clinical safety profile. It has demonstrated potent activity against SARS-CoV-2 [1], influenza [2], and RSV [3] in vitro and animal models of infection.

1. Murray J, Hogan RJ, Martin DE, et al. Probenecid potently inhibits SARS-CoV-2 replication in vivo and in vitro. *Scientific Reports* 2021;11:18085 (<https://doi.org/10.1038/s41598-021-97658-w>).
2. Perwitasari O, Yan X, Johnson S et al. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. *Antimicrob Agents Chemother* 57(1), 475-483 (2013).
3. Murray J, Bergeron H, Shepard J, et al. Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication. *Viruses* 2022, 14, 912.

## About TrippBio, Inc.

TrippBio, Inc. is a Jacksonville, Florida based, clinical development-stage biopharmaceutical company dedicated to commercializing new applications of therapeutics to fight infectious diseases with an emphasis on viral diseases with current efforts focused on identification of drugs to combat infections such as the SARS-CoV-2 virus that causes COVID-19. TrippBio is founded on the scientific research of Ralph Tripp, Ph.D., Georgia Research Alliance Chair and Professor at the University of Georgia. The University of Georgia Research Foundation is a major shareholder of TrippBio, Inc.

## About the University of Georgia

The University of Georgia is the oldest state-chartered institution of higher education in the United States. Spanning more than 750 acres on its main campus alone and employing almost 3,000 faculty members, UGA provides educational and research services to almost 37,000 individuals, including over 8,000 doctoral and professional students. With almost \$500 million in annual research expenditures, and NIH awards totaling more than \$60 million annually, UGA has an estimated \$7.4 billion annual impact on the economy of Georgia. UGA's



18 colleges offer doctoral degrees in 98 areas spanning the liberal arts and humanities; business; journalism; public affairs; law, education, and social work; and include science-based colleges for veterinary medicine, ecology (the first stand-alone college of its type in the world), public health, pharmacy, engineering, and agriculture. The first cohort of medical students was admitted in 2010 to the Augusta University/UGA Medical Partnership, sharing the site of the former Navy Supply Corps School with UGA's College of Public Health in Athens, GA. [www.uga.edu](http://www.uga.edu).

To learn more, please contact us at [info@trippbio.com](mailto:info@trippbio.com)

Dr. David E. Martin

TrippBio, Inc.

[email us here](#)

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/582177284/>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2022 Newsmatics Inc. All Right Reserved.

# TrippBio and University of Georgia Research Foundation Announce Filing of Additional Patent Application

*Filing expands composition of matter and method of use for PanCytoVir™ and analogs against viruses including SARS-CoV-2, Flu, RSV, Measles, Dengue, and Zika*

JACKSONVILLE, FLORIDA, UNITED STATES, August 2, 2022

/EINPresswire.com/ -- TrippBio, Inc. (TrippBio), a clinical development-stage biopharmaceutical company developing antiviral treatments and the University of Georgia Research

Foundation (UGARF), today announced that they have filed a new patent application "Compositions and Methods for Treating and Preventing Viral Infections. The new Patent Cooperation Treaty (PCT) patent broadens the scope of antiviral activity observed with PanCytoVir™ and related analogs to include viral infections including SARS-CoV-2, influenza,

respiratory syncytial virus (RSV), measles, mumps, Dengue, and Zika. Furthermore, it expands the composition of matter to include additional new compounds based on PanCytoVir™ chemistry that have already been prepared and will be investigated in upcoming preclinical studies.

“

Our platform now includes composition of matter for new PanCytoVir™-related analogs and a broader antiviral profile with measles, mumps, Dengue, and Zika in addition to SARS-CoV-2, influenza, and RSV”

*Dr. David E. Martin*

David E. Martin, PharmD, and CEO of TrippBio, Inc., stated, "We are pleased that PanCytoVir™ continues to demonstrate very potent and broad-based antiviral activity against a number of clinically important viruses. In addition to the known activity profile against SARS-CoV-2, RSV, and influenza; PanCytoVir™ has now shown activity

against measles, mumps, Dengue, and Zika. Importantly, the discovery of a number of analogs of PanCytoVir™ should allow for the development of new products optimized to treat these additional infections. We look forward to sharing more on our pipeline expansion in the very



TrippBio, Inc.

near future.”

Dr. Ralph Tripp, Professor of Virology at the University of Georgia and Chief Scientific Officer of TrippBio, Inc. said “PanCytoVir™ has been studied over several years for its antiviral properties. With several new analogs now in development, our patent position is broadening which can lead to a number of new pharmaceutical therapeutics to treat previously untreatable infections.”

#### About PanCytoVir™

PanCytoVir™ (formerly known as TD-213) is a repurposed pharmaceutical approved by the FDA for the treatment of the hyperuricemia associated with gout and can be used as an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin for prolonging drug plasma levels. PanCytoVir™ is a favorable antiviral drug candidate as it is commercially available and has high plasma concentrations with a benign clinical safety profile. It has demonstrated potent activity against SARS-CoV-2, influenza2, and RSV3 in vitro and animal models of infection.

1. Murray J, Hogan RJ, Martin DE, et al. Probenecid potently inhibits SARS-CoV-2 replication in vivo and in vitro. Scientific Reports 2021;11;18085 (<https://doi.org/10.1038/s41598-021-97658-w>).
2. Berwitasari O, Yan X, Johnson S et al. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza virus strategy. Antimicrob Agents Chemother 57(1), 475-483 (2013).
3. Murray J, Bergeron H, Shepard J, et al. Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication. Viruses 2022, 14, 912.

#### About TrippBio, Inc.

TrippBio, Inc. is a Jacksonville, Florida based, clinical development-stage biopharmaceutical company dedicated to commercializing new applications of therapeutics to fight infectious diseases with an emphasis on viral diseases with current efforts focused on identification of drugs to combat infections such as the SARS-CoV-2 virus that causes COVID-19. TrippBio is founded on the scientific research of Ralph Tripp, Ph.D., Georgia Research Alliance Chair and Professor at the University of Georgia. The University of Georgia Research Foundation is a major shareholder of TrippBio, Inc.

#### About the University of Georgia

The University of Georgia is the oldest state-chartered institution of higher education in the United States. Spanning more than 750 acres on its main campus alone and employing almost 3,000 faculty members, UGA provides educational and research services to almost 37,000 individuals, including over 8,000 doctoral and professional students. With almost \$500 million in annual research expenditures, and NIH awards totaling more than \$60 million annually, UGA has an estimated \$7.4 billion annual impact on the economy of Georgia. UGA's 18 colleges offer

doctoral degrees in 98 areas spanning the liberal arts and humanities; business; journalism; public affairs; law, education, and social work; and include science-based colleges for veterinary medicine, ecology (the first stand-alone college of its type in the world), public health, pharmacy, engineering, and agriculture. The first cohort of medical students was admitted in 2010 to the Augusta University/UGA Medical Partnership, sharing the site of the former Navy Supply Corps School with UGA's College of Public Health in Athens, GA. [www.uga.edu](http://www.uga.edu).

To learn more, please contact us at [info@trippbio.com](mailto:info@trippbio.com)

David Eugene Martin

TrippBio, Inc.

[davidmartin@trippbio.com](mailto:davidmartin@trippbio.com)

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/583075459>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.